On May 24, at the 61st European Renal Association Congress in Stockholm, Sweden (this will not be the last glucagon-like peptide-1 receptor agonists talk at Stockholm), Vlado Perkovic presented the previously spoiled results of FLOW. In addition to simultaneous publication in The New England Journal of Medicine, it made the front page in newspapers around the world. As one headline writer said, “Is there anything Ozempic can’t do?”